Bionano Genomics, Inc.
BNGO
$4.00
$0.000.00%
NASDAQ
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Revenue | -23.86% | -34.83% | -10.29% | 18.26% | 30.51% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -23.86% | -34.83% | -10.29% | 18.26% | 30.51% |
| Cost of Revenue | -42.70% | 121.02% | -18.38% | 11.23% | 29.22% |
| Gross Profit | 40.16% | -407.24% | 12.00% | 36.43% | 35.07% |
| SG&A Expenses | -95.48% | -61.99% | -57.09% | -21.67% | -19.21% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -76.68% | -36.57% | -50.78% | -20.28% | -11.26% |
| Operating Income | 96.76% | 37.03% | 59.73% | 27.99% | 20.89% |
| Income Before Tax | 54.19% | 60.70% | 58.34% | 15.25% | -19.13% |
| Income Tax Expenses | 102.78% | -38.46% | -21.21% | -169.23% | -101.99% |
| Earnings from Continuing Operations | 54.15% | 60.69% | 58.31% | 15.36% | -13.48% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 54.15% | 60.69% | 58.31% | 15.36% | -13.48% |
| EBIT | 96.76% | 37.03% | 59.73% | 27.99% | 20.89% |
| EBITDA | 105.38% | 47.46% | 64.44% | 30.13% | 25.09% |
| EPS Basic | 81.52% | 83.98% | 80.57% | 51.52% | 15.38% |
| Normalized Basic EPS | 95.11% | 73.46% | 77.29% | 57.41% | -0.82% |
| EPS Diluted | 81.52% | 83.98% | 80.57% | 51.22% | 15.38% |
| Normalized Diluted EPS | 95.11% | 73.46% | 77.29% | 57.41% | -0.82% |
| Average Basic Shares Outstanding | 148.09% | 145.32% | 114.55% | 74.61% | 34.11% |
| Average Diluted Shares Outstanding | 148.09% | 145.32% | 114.55% | 74.61% | 34.11% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |